Sangamo Therapeutics Inventory Plunges As Pfizer Terminates Hemophilia Gene Treatment Pact
Sangamo Therapeutics Inventory Plunges As Pfizer Terminates Hemophilia Gene Treatment Pact On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the advance and commercialization rights to giroctocogene fitelparvovec, an investigational gene treatment product candidate for
